Skip to content
The Nexus
DossierENTITY

RP1 (vusolimogene oderparepvec)

Coverage of RP1 (vusolimogene oderparepvec) in the Nexus archive.

Earliest in view: Jul 28 · 18:44 UTCMost recent: Aug 2 · 20:00 UTC
Co-mentioned in this coverage
John Carrinoperson1Weill Cornell Medicineorganization1FDA advisory committeeorganization1FDAorganization1melanomatopic1MedPage Todayorganization1
Recent coverage
  • HEALTHAug 2 · 20:00 UTCMEDPAGE TODAY
    'We Should Follow That Signal': What We Heard This Week

    An FDA advisory committee supported RP1 (vusolimogene oderparepvec), a twice-administered treatment, following a statement by John Carrino of Weill Cornell Medicine emphasizing the importance of following observed signals in the data.

  • HEALTHJul 28 · 18:44 UTCMEDPAGE TODAY
    FDA Staff Unconvinced Drug for Melanoma Shows Benefit

    FDA staff remains unconvinced that the melanoma drug candidate RP1 (vusolimogene oderparepvec) demonstrates sufficient benefit. The drug, previously rejected twice by the FDA, faces potential challenges at an upcoming FDA outside experts meeting.